{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:55:00Z","timestamp":1770281700393,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s12094-022-02795-x","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T17:04:50Z","timestamp":1646931890000},"page":"1542-1548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Interval cytoredutive surgery and HIPEC in advanced ovarian cancer with small-bowel disease: results and reflections"],"prefix":"10.1007","volume":"24","author":[{"given":"Pedro Antonio","family":"Cascales Campos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6867-8382","authenticated-orcid":false,"given":"Alida","family":"Gonz\u00e1lez Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro Jes\u00fas","family":"G\u00f3mez Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Balaguer Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Gil G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Alconchel Gago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jer\u00f3nimo","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An\u00edbal","family":"Nieto D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Barcel\u00f3 Valc\u00e1rcel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Gil Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"2795_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71\u201396.","journal-title":"CA Cancer J Clin"},{"key":"2795_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","volume":"124","author":"J Prat","year":"2014","unstructured":"Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet. 2014;124:1\u20135.","journal-title":"Int J Gynecol Obstet"},{"key":"2795_CR3","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer. 2009;115:1234\u201344.","journal-title":"Cancer"},{"key":"2795_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trop\u00e9 CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943\u201353.","journal-title":"N Engl J Med"},{"key":"2795_CR5","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230\u201340.","journal-title":"N Engl J Med"},{"key":"2795_CR6","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1200\/JCO.19.00594","volume":"37","author":"SN Koole","year":"2019","unstructured":"Koole SN, van Lieshout C, van Driel WJ, van Schagen E, Sikorska K, Kieffer JM, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AG, Verwaal VJ, Van Vijver KK, Aaronson NK, van Tinteren H, Sonke GS, van Harten WH, Ret\u00e8l VP. Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trial. J Clin Oncol. 2019;37:2041\u201350.","journal-title":"J Clin Oncol"},{"key":"2795_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1053\/ejso.2002.1380","volume":"29","author":"AA Tentes","year":"2003","unstructured":"Tentes AA, Tripsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, Georgiadis G, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol. 2003;29:69\u201373.","journal-title":"Eur J Surg Oncol"},{"key":"2795_CR8","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1245\/s10434-014-3599-4","volume":"21","author":"PA Cascales-Campos","year":"2014","unstructured":"Cascales-Campos PA, Gil J, Gil E, Feliciangeli E, Gonz\u00e1lez-Gil A, Parrilla JJ, Parrilla P. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC\/IV ovarian cancer. Ann Surg Oncol. 2014;21:2383\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2795_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/jso.20912","volume":"97","author":"L Bijelic","year":"2008","unstructured":"Bijelic L, Sugarbaker PH. Cytoreduction of the small bowel surfaces. J Surg Oncol. 2008;97(2):176\u20139. https:\/\/doi.org\/10.1002\/jso.20912.","journal-title":"J Surg Oncol"},{"key":"2795_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","volume":"221","author":"PH Sugarbaker","year":"1995","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29\u201342.","journal-title":"Ann Surg"},{"key":"2795_CR11","unstructured":"National Cancer Institute, Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v3.0 (CTCAE). 2020. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 09 June 2020."},{"key":"2795_CR12","first-page":"11e23","volume-title":"Advances in peritoneal surface oncology","author":"Y Yonemura","year":"2007","unstructured":"Yonemura Y, Kawamura T, Bandou E, Tsukiyama G, Endou Y, Miura M. The natural history of free cancer cells in the peritoneal cavity. In: Gonzalez- Moreno S, editor. Advances in peritoneal surface oncology. Berlin: Springer-Verlag; 2007. p. 11e23."},{"key":"2795_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ygyno.2019.06.010","volume":"154","author":"A Mariani","year":"2019","unstructured":"Mariani A, Wang C, Oberg AL, Riska SM, Torres M, Kumka J, Multinu F, Sagar G, Roy D, Jung DB, Zhang Q, Grassi T, Visscher DW, Patel VP, Jin L, Staub JK, Cliby WA, Weroha SJ, Kalli KR, Hartmann LC, Kaufmann SH, Goode EL, Shridhar V. Genes associated with bowel metastases in ovarian cancer. Gynecol Oncol. 2019;154:495\u2013504.","journal-title":"Gynecol Oncol"},{"key":"2795_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejso.2020.10.012","volume":"47","author":"A Bhatt","year":"2021","unstructured":"Bhatt A, Bakrin N, Kammar P, Mehta S, Sinukumar S, Parikh L, Shaikh S, Mishra S, Mallaya M, Kepenekian V, Benzerdjeb N, Glehen O. Distribution of residual disease in the peritoneum following neoadjuvant chemotherapy in advanced epithelial ovarian cancer and its potential therapeutic implications. Eur J Surg Oncol. 2021;47:181\u20137.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"2795_CR15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1245\/s10434-020-08649-6","volume":"28","author":"B J\u00f3nsd\u00f3ttir","year":"2021","unstructured":"J\u00f3nsd\u00f3ttir B, Lomnytska M, Poromaa IS, Silins I, St\u00e5lberg K. The peritoneal cancer index is a strong predictor of incomplete cytoreductive surgery in ovarian cancer. Ann Surg Oncol. 2021;28(1):244\u201351.","journal-title":"Ann Surg Oncol"},{"key":"2795_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/IGC.0000000000001173","volume":"28","author":"M Rosendahl","year":"2018","unstructured":"Rosendahl M, Harter P, Bj\u00f8rn SF, H\u00f8gdall C. Specific regions, rather than the entire peritoneal carcinosis index, are predictive of complete resection and survival in advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2018;28:316\u201322.","journal-title":"Int J Gynecol Cancer"},{"key":"2795_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1136\/ijgc-2018-000154","volume":"29","author":"AA Gockley","year":"2019","unstructured":"Gockley AA, Fiascone S, Hicks Courant K, Pepin K, Del Carmen M, Clark RM, Goldberg J, Horowitz N, Berkowitz R, Worley M Jr. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma. Int J Gynecol Cancer. 2019;29:585\u201392.","journal-title":"Int J Gynecol Cancer"},{"key":"2795_CR18","first-page":"324e30","volume":"33","author":"MC Lim","year":"2010","unstructured":"Lim MC, Song YJ, Seo SS, et al. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer. Onkologie. 2010;33:324e30.","journal-title":"Onkologie"},{"key":"2795_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ygyno.2015.06.012","volume":"139","author":"P Cascales-Campos","year":"2015","unstructured":"Cascales-Campos P, Gil J, Feliciangeli E, Parrilla P. HIPEC in ovarian cancer: treatment of a new era or is it the end of the pipeline? Gynecol Oncol. 2015;139:363\u20138.","journal-title":"Gynecol Oncol"},{"key":"2795_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejso.2017.11.003","volume":"44","author":"A Llueca","year":"2018","unstructured":"Llueca A, Escrig J, MUAPOS working group (Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery). Prognostic value of peritoneal cancer index in primary advanced ovarian cancer. Eur J Surg Oncol. 2018;44:163\u20139.","journal-title":"Eur J Surg Oncol"},{"key":"2795_CR21","doi-asserted-by":"publisher","first-page":"20190018","DOI":"10.1515\/pp-2019-0018","volume":"4","author":"J Spiliotis","year":"2019","unstructured":"Spiliotis J, Kalles V, Kyriazanos I, Terra A, Prodromidou A, Raptis A, Kopanakis N, Christopoulou A. CRS and HIPEC in patients with peritoneal metastasis secondary to colorectal cancer: the small-bowel PCI score as a predictor of survival. Pleura Peritoneum. 2019;4:20190018.","journal-title":"Pleura Peritoneum"},{"key":"2795_CR22","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.ejrad.2016.08.006","volume":"85","author":"V Lopez-Lopez","year":"2016","unstructured":"Lopez-Lopez V, Cascales-Campos PA, Gil J, Frutos L, Andrade RJ, Fuster-Qui\u00f1onero M, Feliciangeli E, Gil E, Parrilla P. Use of (18)F-FDG PET\/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue. Eur J Radiol. 2016;85:1824\u20138.","journal-title":"Eur J Radiol"},{"key":"2795_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1245\/s10434-017-6235-2","volume":"25","author":"M Petrillo","year":"2018","unstructured":"Petrillo M, Nero C, Carbone V, Bruno M, Scambia G, Fagotti A. Systematic review of cytoreductive surgery and bevacizumab-containing chemotherapy in advanced ovarian cancer: focus on safety. Ann Surg Oncol. 2018;25:247\u201354.","journal-title":"Ann Surg Oncol"},{"key":"2795_CR24","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX, Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473\u201383.","journal-title":"N Engl J Med"},{"key":"2795_CR25","first-page":"CD005340","volume":"1","author":"K Jaaback","year":"2016","unstructured":"Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016;1:CD005340.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02795-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-022-02795-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02795-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T16:18:51Z","timestamp":1657815531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-022-02795-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["2795"],"URL":"https:\/\/doi.org\/10.1007\/s12094-022-02795-x","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,10]]},"assertion":[{"value":"25 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable. Information is anonymized and the submission does not include images that may identify the person.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}